Cimzia® is a PEGylated, humanized antigen-binding mAb fragment TNF inhibitor that was launched by UCB in 2008 and has been used in tens of thousands of patients.  Cimzia is currently approved and marketed by UCB for the treatment of numerous inflammatory diseases in multiple countries, including the United States, and has previously completed two Phase 2 clinical trials in moderate-to-severe plaque psoriasis.  Cimzia is not currently approved for the treatment of plaque psoriasis.

Dermira has entered into a collaboration agreement with UCB to broaden patient access by developing Cimzia for the treatment of moderate-to-severe chronic plaque psoriasis in the United States, Canada and the European Union and, upon regulatory approval, marketing Cimzia to dermatologists in the United States and Canada.